The impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.
Thomas Unger
Advertisement
Thomas Unger, PhD, MBA, is an Associate Director at Arthur D. Little.
Articles by Thomas Unger
Advertisement
Latest Updated Articles
- Managing the 3 Fronts of the Drug Pricing Conundrum: Policy, Creativity, Collaboration
Published: August 27th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
2
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
3
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
4
Evolution of Biotech CFOs
5
